Table 2 Patients’ clinical and demographic characteristics, procedural indications, and medication dosages
Male, n (%) | 128/200 (64) |
Mean age ± SD, (years) | 56.3 ± 15.2 |
ASA score, n (%) | |
I | 7 (3.5) |
II | 73 (36.5) |
III | 119 (59.5) |
IV | 1 (0.5) |
Disorder, n (%) | |
Hepatic | 127/200 (63.5) |
Gastrointestinal | 31/200 (15.5) |
Postoperative | 20/200 (10) |
Other disorders | 22/200 (11) |
Procedural indications, n (%) | |
Malignant jaundice | 58/200 (29) |
Stricture after LTX | 45/200 (22.5) |
Stones/sludge | 37/200 (18.5) |
Postoperative complications | 18/200 (9) |
Other reasons | 42/200 (21) |
Medication dosages | |
Propofol mean dose ± SD, (mg) | 287 ± 134 |
Propofol mean dosage ± SD, (mg/kg) | 3.8 ± 1.7 |
Remifentanil mean dose ± SD, (μg) | 135 ± 68 |
Remifentanil mean dosage ± SD, (μg/kg) | 1.8 ± 1.0 |